AR108642A1 - Benzimidazoles sustituidos como inhibidores de irak4 y su uso para la preparación de medicamentos - Google Patents

Benzimidazoles sustituidos como inhibidores de irak4 y su uso para la preparación de medicamentos

Info

Publication number
AR108642A1
AR108642A1 ARP170101476A ARP170101476A AR108642A1 AR 108642 A1 AR108642 A1 AR 108642A1 AR P170101476 A ARP170101476 A AR P170101476A AR P170101476 A ARP170101476 A AR P170101476A AR 108642 A1 AR108642 A1 AR 108642A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogen
substituted
membered heteroaryl
endometriosis
Prior art date
Application number
ARP170101476A
Other languages
English (en)
Inventor
Siebeneicher Holger Dr
Andres Dorothee Dr
Schmidt Nicole Dr
Gnther Judith Dr
Bmer Ulf Dr
Nubbemeyer Reinhard Dr
Bothe Ulrich Dr
Sven Ring
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AR108642A1 publication Critical patent/AR108642A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud se refiere a benzimidazoles sustituidos, a su uso solos o en combinación para el tratamiento y/o la profilaxis de enfermedades, así como su uso para la preparación de medicamentos para el tratamiento y/o la profilaxis de enfermedades; en particular para el tratamiento y/o la profilaxis de endometriosis, así como dolores asociados a la endometriosis y otros síntomas de endometriosis como dismenorrea, dispareunia, disuria y disquecia, de linfomas, artritis reumatoidea, espondiloartritis (en particular espondiloartritis psoriásica y enfermedad de Bechterew), lupus eritematoso sistémico, esclerosis múltiple, degeneración macular, EPOC, gota, afecciones por hígado graso, resistencia a la insulina, enfermedades tumorales y psoriasis. Reivindicación 1: Compuestos de la fórmula general (1) caracterizados porque R¹ representa un heteroarilo de 5 ó 6 miembros, que contiene 1 ó 2 heteroátomos iguales o diferentes seleccionados del grupo O, S y N y está enlazado mediante un átomo de carbono anular, donde un heteroarilo de 5 miembros puede estar monosustituido con cicloalquilo C₃₋₆ o alquilo C₁₋₃, que puede estar sustituido con halógeno y donde en el caso que el heteroarilo de 5 miembros significa pirazolilo, pirazolilo puede estar monosustituido en N con cicloalquilo C₃₋₆ o alquilo C₁₋₃, que puede estar sustituido con halógeno; y donde un heteroarilo de 6 miembros puede estar mono- o disustituido de manera igual o diferente con halógeno, alcoxi C₁₋₃, NH₂, alquilo C₁₋₃, que puede estar sustituido con halógeno; A representa un enlace o alquilo C₁₋₆; R² en el caso que A sea alquilo C₁₋₆, representa hidrógeno, alcoxi C₁₋₃, S(=O)₂-alquilo C₁₋₃, NH(alquilo C₁₋₃), N(alquilo C₁₋₃)₂ o un heterocicloalquilo de 4, 5 ó 6 miembros, que contiene uno o dos heteroátomos iguales o diferentes o grupos de heteroátomos seleccionados de O, S, S(=O)₂, N, NH, N(alquilo C₁₋₃) y está enlazado ya sea mediante un átomo de carbono anular o un átomo de nitrógeno anular o R² en el caso que A sea un enlace, representa alquilo C₁₋₆, que puede estar monosustituido con -OH, o representa un heterocicloalquilo de 5 ó 6 miembros, que contiene un heteroátomo o un grupo de heteroátomos seleccionados de N(alquilo C₁₋₃), O, S(=O)₂ y está enlazado por medio de un átomo de carbono anular del heterocicloalquilo, y sus diastereómeros, enantiómeros, sus metabolitos, sus sales, sus solvatos o los solvatos de sus sales.
ARP170101476A 2016-05-31 2017-05-31 Benzimidazoles sustituidos como inhibidores de irak4 y su uso para la preparación de medicamentos AR108642A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16172162 2016-05-31

Publications (1)

Publication Number Publication Date
AR108642A1 true AR108642A1 (es) 2018-09-12

Family

ID=56096532

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101476A AR108642A1 (es) 2016-05-31 2017-05-31 Benzimidazoles sustituidos como inhibidores de irak4 y su uso para la preparación de medicamentos

Country Status (4)

Country Link
AR (1) AR108642A1 (es)
TW (1) TW201803866A (es)
UY (1) UY37267A (es)
WO (1) WO2017207340A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4142717A4 (en) * 2020-04-28 2024-05-29 Kymera Therapeutics Inc IRAQ INHIBITORS AND USES THEREOF
WO2022156788A1 (zh) * 2021-01-22 2022-07-28 武汉人福创新药物研发中心有限公司 苯并咪唑化合物及其用途
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH23995A (en) * 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
GB9306578D0 (en) 1993-03-30 1993-05-26 Merck Sharp & Dohme Therapeutic agents
EP1255750A1 (en) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa
ES2367422T3 (es) 2001-10-09 2011-11-03 Amgen Inc. Derivados de imidazol como agentes antiinflamatorios.
EP1499305A2 (en) 2002-04-12 2005-01-26 Pfizer Japan Inc. Use of ep4 receptor ligands in the treatment of il-6 involved diseases
AU2003252715B2 (en) * 2002-07-30 2009-06-04 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
JP4909068B2 (ja) 2003-02-14 2012-04-04 グラクソ グループ リミテッド カルボキサミド誘導体
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CA2591332A1 (en) 2004-12-08 2006-06-15 Warner-Lambert Company Llc Methylene inhibitors of matrix metalloproteinase
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
AU2008240313A1 (en) 2007-04-13 2008-10-23 Aj Park Aminopyrimidines useful as kinase inhibitors
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CA2740095A1 (en) 2008-10-10 2010-04-15 Celtaxsys, Inc. Method of inducing negative chemotaxis
US20140113898A1 (en) 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
BR112013020270A2 (pt) 2011-02-10 2016-07-12 Syngenta Participations Ag derivados de pirazol microbicidas
US10385070B2 (en) 2011-02-18 2019-08-20 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
BR112014030940B1 (pt) 2012-06-11 2022-09-06 UCB Biopharma SRL Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途

Also Published As

Publication number Publication date
UY37267A (es) 2018-01-02
TW201803866A (zh) 2018-02-01
WO2017207340A1 (de) 2017-12-07

Similar Documents

Publication Publication Date Title
AR103138A1 (es) Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos
AR102827A1 (es) Indazoles sustituidos, procedimientos para su preparación y preparaciones farmacéuticas que los contienen
CO2021016018A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
CO2021016015A2 (es) Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CL2020001546A1 (es) Compuestos de 4-azaindol.
AR106472A1 (es) Inhibidores de acc y usos de los mismos
AR107795A1 (es) Indazoles 2-sustituidos, procedimientos para su preparación, y su uso para la preparación de medicamentos
CO2017006214A2 (es) Derivados de quinazolina utilizados para tratar el vih
AR107519A1 (es) Compuestos de piperidina sustituido y su uso
CL2019001664A1 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos.
AR106605A1 (es) Oxadiazoles sustituidos para combatir hongos fitopatógenos
BR112016029846A2 (pt) ?composto, composição farmacêutica, métodos para o método para tratamento de um humano, para inibição da atividade de um polipeptídio de fosfatidilinositol 3-quinase e inibição excessiva ou reações imunes destrutivas ou crescimento ou uma proliferação de células de câncer, kit, e, uso de um composto, um sal farmaceuticamente aceitável, isômero, ou uma mistura do mesmo?
EA201692010A1 (ru) Фармацевтическое соединение
NI201500130A (es) 2-azabiciclo sustituidos y su uso como moduladores del receptor de orexina
AR091193A1 (es) HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
CU20170026A7 (es) Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf
AR100984A1 (es) Método para producir un compuesto heterocíclico fusionado
AR108642A1 (es) Benzimidazoles sustituidos como inhibidores de irak4 y su uso para la preparación de medicamentos
CO2018002211A2 (es) Piridinona dicarboxamida para su uso como inhibidores de bromodominio
BR112016028814A2 (pt) ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo?
AR108387A1 (es) Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor
AR098432A1 (es) Compuestos heterocíclicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure